Clinical Trial Search

Primary: Annualized Number of Bleeding Episodes. — 32.9; 3.6 Number of bleeds per year — p=<0.0001

Primary: Percentage of Participants With a Response as Determined by American College of Rheumatology (ACR) 20% Improvement (ACR20) — 64.2; 63.9; 72.0 percentage of participants…

Primary: Number of Participants With Adverse Events — 100; 42 participants

Primary: Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin — -0.88; -0.27 Percent of…

Primary: Proportion of Patients With Restored CVAD Function at 120 Min After Administration of the First Dose of Study Medication — 83.3; 10.0 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 89.5; 84.8; 84.0; 90.9 percentage of participants

Primary: Rate of Subjects With PRNT50 Titers of ≥ 1:10 at Month 12 After the First IC51 Vaccination (in Study IC51-322) — 89.5 percentage of participants

Primary: Change in Caregiver Burden From Baseline — 32.04; 28.59; 32.52; 27.55 units on a scale — p=.51

Primary: Disease-free Survival — 64; 71; 70 percentage of participants

Primary: Change From Baseline Hemoglobin at End-of-Treatment: Least-Squares Mean — 0.6; -3.0 grams per liter — p=0.011

Primary: Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term…

Primary: Number of Cumulus-oocyte-complexes Retrieved, Per Attempt — 13.3; 10.6 Number of cumulus-oocyte-complexes — p=<0.001

Primary: Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs — 3; 5; 8; 0 participants

Primary: Change From Baseline Hemoglobin at End-of-Treatment: Least-Squares Mean — -0.5; -4.0 grams per liter — p=0.011

Primary: Progression-free Survival — 8.0; 4.0 months — p=0.078